Pulsing with immunogenic multiepitope MHC class II HER2 peptides and the generation of a host specific anti-HER2 immune response was critical for the tumor regression efficacy of HER2-DC1 i.t. combined with anti-HER2 antibodies treatment, which was supported by the failure of controlling HER2pos TUBO tumor growth after autologous unpulsed DC1 i.t. or allogenic HER2-DC1 i.t. combined with anti-HER2 antibodies treatment (figure 2C). Here, ERBB2 is linked to neoplasm.